Home › Markets › Health Care › CADL

Candel Therapeutics Inc. (CADL)

CADL trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · October 14, 2026
$9.27
-5.21% on the day
Market cap
$709.3M
Small cap
Revenue
No annual revenue filed since the period ending 2022-12-31
Net income
No annual revenue filed since the period ending 2022-12-31

Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026.

Profile

FieldValue
TickerCADL on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO year2021
SEC CIK0001841387
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inDE

Financials

No annual revenue filed since the period ending 2022-12-31.

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-02-20
Latest annual report10-K2026-03-12
Latest quarterly / interim10-Q2026-08-13
Latest current report8-K2026-09-10
Latest proxyDEFA14A2026-04-29

Source: SEC EDGAR submissions feed, 416 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-6.9%
1 month-17.8%
3 months-3.6%
Year to date+61.8%
1 year+41.3%
From 52-week high-33.5%

Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
SANASana Biotechnology Inc.$2.41-8.02%$721.5M
FDMT4D Molecular Therapeutics Inc.$12.36-4.92%$682.8M
ATTOAttovia Therapeutics Inc.$14.72+0.89%$672.0M
DNAGinkgo Bioworks Holdings Inc.$11.76-0.25%$756.6M
AURAAura Biosciences Inc.$6.27-4.13%$650.2M
SLDBSolid Biosciences Inc.$5.82-13.26%$624.1M
ODTXOdyssey Therapeutics Inc.$17.24-5.59%$828.5M
PRMEPrime Medicine Inc.$3.32-8.03%$602.2M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier